The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Amnesty International has received reports of violence against lesbians in Jamaica, including rape and other forms of sexual violence. Lesbians reportedly have been attacked on the grounds of masculine physical appearance or other visible signs of sexuality. Some reports of abduction and rape come from inner-city communities, where local non-governmental organizations have expressed concerns about high incidents of violence against women.
polyadenylation The addition of a series of multiple adenosine ribonucleotides, known as a poly(A) tail, to the 3'-end of a primary RNA transcript. A class of post-transcriptional modification, polyadenylation serves different purposes for different classes of RNA and in different cell types and organisms. For eukaryotic messenger RNAs, the addition of a poly(A) tail is an important step in the processing of the raw transcript into a mature mRNA ready for export to the cytoplasm; primary transcripts are first cleaved 10–30 nucleotides downstream of a highly conserved AAUAAA sequence, then the poly(A) tail is generated from the chaining of multiple ATP molecules through the action of polynucleotide adenylyltransferase.For non-coding RNAs and in many bacteria, polyadenylation has the opposite function, instead promoting the RNA's degradation.
C6H5OH + Hg(O2CCH3)2 → C6H4(OH)–HgO2CCH3 + CH3CO2H C6H4(OH)–HgO2CCH3 + NaCl → C6H4(OH)–HgCl + NaO2CCH3 The first such reaction, including a mercuration of benzene itself, was first reported by Otto Dimroth in 1898.
=== Metalloaminopeptidases === Metalloaminopeptidases require metal ions, such as zinc or manganese, in order to function. These enzymes can be identified by a conserved HEXXH motif in their active site. This motif is crucial for the enzyme's function, as the histidine amino acids within the motif coordinate (bind) the metal ion, which then uses hydrolysis to break the peptide bond between the first amino acid and the rest of the protein. Metalloaminopeptidases are the largest and most homogenous class of aminopeptidases; the MEROPS database identifies over 35 families to be part of the MA clan. This classification, which is based on structural similarities and evolutionary relationships, indicates a common ancestral origin for these enzymes. Examples of metalloaminopeptidases include aminopeptidase N (APN), leucine aminopeptidase (LAP), and aminopeptidase A (APA).
The sixth row of the table likewise starts with two s-block elements: caesium and barium. After this, the first f-block elements (coloured green below) begin to appear, starting with lanthanum. These are sometimes termed inner transition elements. As there are now not only 4f but also 5d and 6s subshells at similar energies, competition occurs once again with many irregular configurations; this resulted in some dispute about where exactly the f-block is supposed to begin, but most who study the matter agree that it starts at lanthanum in accordance with the Aufbau principle. Even though lanthanum does not itself fill the 4f subshell as a single atom, because of repulsion between electrons, its 4f orbitals are low enough in energy to participate in chemistry. At ytterbium, the seven 4f orbitals are completely filled with fourteen electrons; thereafter, a series of ten transition elements (lutetium through mercury) follows, and finally six main-group elements (thallium through radon) complete the period. From lutetium onwards the 4f orbitals are in the core, and from thallium onwards so are the 5d orbitals. The seventh row is analogous to the sixth row: 7s fills (francium and radium), then 5f (actinium to nobelium), then 6d (lawrencium to copernicium), and finally 7p (nihonium to oganesson). Starting from lawrencium the 5f orbitals are in the core, and probably the 6d orbitals join the core starting from nihonium.
Sources: en.wikipedia.org
Long-term exposure to air pollution may increase the risk of developing Parkinson's disease (PD). Components including particulate matter (PM2.5) and gases such as nitrogen dioxide (NO2), nitrogen oxides generally, ozone (O3) and carbon monoxide (CO) are associated with increased risk for PD. Higher PM2.5 levels correlate with increased PD hospitalization rates, for both short-term and long-term exposure. Air pollution is linked to Parkinson's disease through mechanisms of oxidative stress. PM2.5, NOx, and polycyclic aromatic hydrocarbons (PAHs) can cause the formation of reactive oxygen species (ROS). If there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to detoxify itself, this can lead to neuronal damage. Long-term exposure to air pollutants may lead to chronic oxidative stress and contribute to the progressive development of PD. Air pollution is also linked to increased risk of Parkinson's disease through mechanisms of systemic inflammation, neuroinflammation, and neuronal loss. Components of air pollution, particularly smaller particles, can reach the brain directly and contribute to PD pathology through direct neurotoxic effects or neuroinflammation. Exposure to air pollution can also cause peripheral inflammation of the lungs and other tissues, which can lead to systemic inflammation, weakening of the blood–brain barrier (BBB), and increased neuroinflammation.
Hemostasis occurs when blood is present outside of the body or blood vessels. It is the innate response for the body to stop bleeding and loss of blood. During hemostasis three steps occur in a rapid sequence. Vascular spasm is the first response as the blood vessels constrict to allow less blood to be lost. In the second step, platelet plug formation, platelets stick together to form a temporary seal to cover the break in the vessel wall. The third and last step is called coagulation or blood clotting. Coagulation reinforces the platelet plug with fibrin threads that act as a "molecular glue". Platelets are a large factor in the hemostatic process. They allow for the creation of the "platelet plug" that forms almost directly after a blood vessel has been ruptured. Within seconds of a blood vessel's epithelial wall being disrupted, platelets begin to adhere to the sub-endothelium surface. It takes approximately sixty seconds until the first fibrin strands begin to intersperse among the wound. After several minutes the platelet plug is completely formed by fibrin. Hemostasis is maintained in the body via three mechanisms:
The chloroplasts of some hornworts and algae contain structures called pyrenoids. They are not found in higher plants. Pyrenoids are roughly spherical and highly refractive bodies which are a site of starch accumulation in plants that contain them. They consist of a matrix opaque to electrons, surrounded by two hemispherical starch plates. The starch is accumulated as the pyrenoids mature. In algae with carbon concentrating mechanisms, the enzyme RuBisCO is found in the pyrenoids. Starch can also accumulate around the pyrenoids when CO2 is scarce. Pyrenoids can divide to form new pyrenoids, or be produced "de novo".
Outline of Germany Schleswig Holstein-Glückstadt Dukes of Holstein-Gottorp Schleswig-Holstein-Sonderburg Schleswig-Holstein-Sonderburg-Glücksburg Schleswig-Holstein-Sonderburg-Beck Schleswig-Holstein-Sonderburg-Augustenburg Schleswig-Holstein-Sonderburg-Plön Schleswig-Holstein-Sonderburg-Norburg Schleswig-Holstein-Sonderburg-Plön-Rethwisch State Constitutional Court of Schleswig-Holstein Coat of arms of Schleswig Region Sønderjylland-Schleswig Schleswig-Holstein Police
Sources: en.wikipedia.org
=== 1994–1996: Nagoya Grampus Eight === Shortly after his dismissal, Wenger travelled to the United Arab Emirates to attend a series of conferences held by FIFA. Wenger was a member of the football governing body's technical committee, responsible for analysing the 1994 World Cup, and made a presentation to coaches of emerging football nations. His speech was closely followed by Japanese delegates, whose country had invested millions into the restructuring of its football league system. Representatives of Toyota, the majority owner of Nagoya Grampus Eight soon met with Wenger and offered him the chance to become the club's manager. Wenger deliberated, even though the idea of working abroad appealed to him; negotiations between the two parties lasted for two months. In that time, he sought the advice of his closest friends and family, and flew to Japan to watch Nagoya Grampus' striker Gary Lineker make his final appearance before his professional retirement. In December 1994, Wenger agreed to become manager of Nagoya Grampus, on a two-year contract worth ¥75m annually.
On 8 March, Pakistani officials stated that since the start of hostilities, 583 Afghan Taliban operatives had been killed and more than 795 injured. They added that Pakistani forces had destroyed 242 check-posts, captured 38 others, destroyed 213 tanks, armored vehicles, and artillery guns, and targeted 64 locations across Afghanistan in air strikes. Pakistani officials also said that they foiled an infiltration attempt along the Pakistan–Afghanistan border near the Chaman sector, killing one Taliban soldier while others fled the area. Elsewhere, Pakistani security forces carried out intelligence-based operation in five districts of the country, killing 13 Pakistani Taliban militants. In Pakistan's North Waziristan, two civilians were killed and three others were injured when a mortar shell fired by Taliban forces landed in a village. A child was killed and his 11 family members were wounded in a quadcopter strike in South Waziristan. Meanwhile, Taliban officials said that they shot a reconnaissance drone belonging to Pakistani forces in Nangarhar province. Two militants were killed in a Pakistani precision airstrike in Bannu District. In Kunar province, residents stated that the Taliban had forced them to participate in a protest march against Pakistan in Asadabad on 7 March. According to them, Taliban authorities instructed each tribal elder to bring at least five people to the protest.
On 21 March, Japanese ambassador to Brazil Teiji Hayashi confirmed that prime minister Fumio Kishida would invite president Lula to the 49th G7 summit to be held from 19 to 21 May 2023 in Hiroshima, which formally took place on 6 April. In May 2023, Kishida met with Lula and announced that Japan was starting procedures to grant Brazilians travel visa exemptions and was opening a ¥30 billion line of credit to support health companies and other businesses in Brazil through Japan International Cooperation Agency (JICA). Lula said Brazil and Japan need to further develop their commercial, cultural, political and scientific relationship adding that "we have cultural bonds with Japan and a great Japanese-Brazilian community". Both leaders also discussed education, climate change, development and peace.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.